Quantifying the Utility of Taking Pills for Cardiovascular Prevention

Circulation: Cardiovascular Quality and Outcomes

Volumn 8, Issue 2, 2015, Pages 155-163

  Hutchins, Robert ^a   Viera, Anthony J ^b,c,d,e   Sheridan, Stacey L ^b,c,d   Pignone, Michael P ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Health Care and Prevention MD MPH Program   (United States)

^c IL   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e Department of Family Medicine ^*  (United States)

Author keywords

Cost utility analysis; prevention and control

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CARDIOVASCULAR AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; FEMALE; HEALTH SURVEY; HUMAN; INTERNET; MALE; PILL; PRIORITY JOURNAL; UNITED STATES; ATTITUDE TO HEALTH; CARDIOVASCULAR DISEASES; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; DRUG COST; ECONOMICS; GAMBLING; HEALTH CARE COST; HEALTH CARE SURVEY; MEDICATION COMPLIANCE; MIDDLE AGED; POLYPHARMACY; PREVENTIVE HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; AGED; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DRUG COSTS; FEMALE; GAMBLING; HEALTH CARE SURVEYS; HEALTH EXPENDITURES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERNET; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POLYPHARMACY; PREVENTIVE HEALTH SERVICES; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84928920609     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.114.001240     Document Type: Article

References (34)

1. Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med. 2007;167:290-295. doi: 10.1001/archinte.167.3.290.
2. Greving JP, Visseren FL, de Wit GA, Algra A. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ. 2011;342:d1672.
3. Naglie IG, Detsky AS. Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. Med Decis Making. 1992;12:239-249.
4. Nease RF Jr, Kneeland T, O'Connor GT, Sumner W, Lumpkins C, Shaw L, Pryor D, Sox HC. Variation in patient utilities for outcomes of the management of chronic stable angina: implications for clinical practice guidelines. JAMA. 1995;273:1185-1190.
5. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chronic Dis. 1978;31:697-704.
6. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis. 1987;40:593-603.
7. Torrance GW, Furlong W, Feeny D. Health utility estimation. Expert Rev Pharmacoecon Outcomes Res. 2002;2:99-108. doi: 10.1586/14737167.2.2.99.
8. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 2010;13:1065.
9. Ryan M, Scott DA, Reeves C, Bate A, van Teijlingen ER, Russell EM, Napper M, Robb CM. Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess. 2001;5:1-186.
10. Dolan P, Gudex C, Kind P, Williams A. Valuing health states: a comparison of methods. J Health Econ. 1996;15:209-231.
11. Flowers CR, Garber AM, Bergen MR, Lenert LA. Willingness-to-pay utility assessment: feasibility of use in normative patient decision support systems. Proc AMIA Annu Fall Symp. 1997:223-227.
12. Olsen JA, Smith RD. Theory versus practice: a review of 'willingness-topay' in health and health care. Health Econ. 2001;10:39-52.
13. Brennan VK, Dixon S. Incorporating process utility into quality adjusted life years: a systematic review of empirical studies. Pharmacoeconomics. 2013;31:677-691. doi: 10.1007/s40273-013-0066-1.
14. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829-1836.
15. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.
16. Fontana M, Asaria P, Moraldo M, Finegold J, Hassanally K, Manisty CH, Francis DP. Patient-accessible tool for shared decision making in cardiovascular primary prevention: balancing longevity benefits against medication disutility. Circulation. 2014;129:2539-2546. doi: 10.1161/CIRCULATIONAHA.113.007595.
17. Augustovski FA, Cantor SB, Thach CT, Spann SJ. Aspirin for primary prevention of cardiovascular events. J Gen Intern Med. 1998;13: 824-835.
18. Coleman CI, Straznitskas AD, Sobieraj DM, Kluger J, Anglade MW. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. Am J Cardiol. 2012;109:1020-1025. doi: 10.1016/j.amjcard.2011.11.034.
19. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150:73-83.
20. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1-11. doi: 10.7326/0003-4819-154-1-201101040-00289.
21. Lee S, Mullin R, Blazawski J, Coleman CI. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS One. 2012;7:e47473. doi: 10.1371/journal.pone.0047473.
22. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Costeffectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012;110:845-851. doi: 10.1016/j. amjcard.2012.05.011.
23. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 2005;293:699-706. doi: 10.1001/jama.293.6.699.
24. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006;144:326-336.
25. Pignone M, Earnshaw S, McDade C, Pletcher MJ. Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men. J Gen Intern Med. 2013;28:1483-1491. doi: 10.1007/s11606-013-2465-6.
26. Pink J, Pirmohamed M, Hughes DA. Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. Clin Pharmacol Ther. 2013;94:269-276. doi: 10.1038/clpt.2013.83.
27. Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150:243-254.
28. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562-2570. doi: 10.1161/CIRCULATIONAHA.110.985655.
29. Weinstein MC, Stason WB. Economic considerations in the management of mild hypertension. Ann N Y Acad Sci. 1978;304:424-440.
30. Puhan MA, Schünemann HJ, Wong E, Griffith L, Guyatt GH. The standard gamble showed better construct validity than the time trade-off. J Clin Epidemiol. 2007;60:1029-1033. doi: 10.1016/j.jclinepi.2007.03.001.
31. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chronic Dis. 1978;31:697-704.
32. van Wijck EE, Bosch JL, Hunink MG. Time-tradeoff values and standardgamble utilities assessed during telephone interviews versus face-to-face interviews. Med Decis Making. 1998;18:400-405.
33. Woloshin S, Schwartz LM, Moncur M, Gabriel S, Tosteson AN. Assessing values for health: numeracy matters. Med Decis Making. 2001;21:382-390.
34. Morris NS, MacLean CD, Chew LD, Littenberg B. The Single Item Literacy Screener: evaluation of a brief instrument to identify limited reading ability. BMC Family Practice. 2006;7:21.